Synbiotic SE Logo

Synbiotic SE

SBX | F

Overview

Corporate Details

ISIN(s):
DE000A351MG9 (+6 more)
LEI:
48510041U2G1IWA3R418
Country:
Germany
Address:
Münsterstr. 336, 40470 Düsseldorf
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SynBiotic SE is a leading European publicly listed corporate group focused on the industrial hemp and cannabis market. The company pursues a pan-European "buy and build" investment strategy to create a vertically integrated platform. Its operations encompass the entire value chain, from cultivation, research, and development to the production, distribution, and retail of industrial hemp, medical cannabis, and recreational cannabis products. By investing in and integrating promising ventures, SynBiotic SE aims to build a comprehensive ecosystem to capitalize on the growth of the European cannabis sector.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Synbiotic SE. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-14 11:19
Regulatory News Service
Across the pond: SYNBIOTIC attracts international investors with established in…
English 10.2 KB
2025-07-29 12:54
Business and Financial Review
Revenue expected to triple by 2027: Focus on growth markets for medical cannabi…
English 10.9 KB
2025-06-11 11:48
Regulatory News Service
Successful roadshow continues: SYNBIOTIC keeps expanding its presence in the ca…
English 9.3 KB
2025-04-23 09:24
Director's Dealing
SYNBIOTIC SE: HempConsult GmbH, Lending (free of charge) of 50,000 shares as p…
English 6.1 KB
2025-04-18 14:14
Share Issue/Capital Change
IRIS Capital invests in SYNBIOTIC's growth strategy
English 8.7 KB
2025-04-17 13:21
Capital/Financing Update
SYNBIOTIC SE: STRATEGISCHE PARTNERSCHAFT MIT IRIS CAPITAL INVESTMENT
German 6.8 KB
2025-04-01 15:13
Regulatory News Service
SYNBIOTIC presents medical cannabis as a pastille for the German market for the…
English 8.7 KB
2025-03-14 11:14
Regulatory News Service
Quo vadis legalisation: SYNBIOTIC and GOC NEXUS at the International Cannabis B…
English 11.3 KB
2025-03-13 11:14
Regulatory News Service
Quo vadis legalisation: SYNBIOTIC and GOC NEXUS at the International Cannabis B…
English 11.3 KB
2025-01-11 11:44
M&A Activity
SYNBIOTIC with four new investments in 2024: Further acquisitions in sight for …
English 10.0 KB
2025-01-10 11:44
M&A Activity
SYNBIOTIC with four new investments in 2024: Further acquisitions in sight for …
English 10.0 KB
2024-12-19 13:06
Regulatory News Service
Trend-setting decontamination: SYNBIOTIC and GOC NEXUS set the gold standard fo…
English 10.2 KB
2024-12-18 13:06
Regulatory News Service
Trend-setting decontamination: SYNBIOTIC and GOC NEXUS set the gold standard fo…
English 10.2 KB
2024-12-14 16:45
Regulatory News Service
SYNBIOTIC SE geht mit der GOC NEXUS OPERATIONS GMBH strategische Partnerschaft …
German 6.8 KB
2024-12-13 12:24
Regulatory News Service
SYNBIOTIC SE: Einbringung der CannaCare Health GmbH wird nicht durchgefuhrt.
German 6.4 KB

Automate Your Workflow. Get a real-time feed of all Synbiotic SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Synbiotic SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-11-13 Otto, Frank Supervisory board Other None 1,085,723.60 EUR
2023-11-28 Kruse, Daniel Other Buy None 19,794.19 EUR
2023-11-28 Kruse, Daniel Other Buy None 297.00 EUR
2023-10-23 Otto, Frank Supervisory board Other None 354,474.00 EUR

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK